Balyasny Asset Management’s Maravai LifeSciences MRVI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-35,821
Closed -$103K 3388
2025
Q3
$103K Buy
+35,821
New +$91.5K ﹤0.01% 2786
2024
Q4
Sell
-315,686
Closed -$2.62M 3079
2024
Q3
$2.62M Buy
315,686
+262,248
+491% +$2.27M ﹤0.01% 1561
2024
Q2
$383K Sell
53,438
-432,767
-89% -$3.74M ﹤0.01% 2150
2024
Q1
$4.22M Sell
486,205
-9,221
-2% -$62.4K 0.01% 1289
2023
Q4
$3.25M Sell
495,426
-82,061
-14% -$530K 0.01% 1291
2023
Q3
$5.77M Sell
577,487
-101,716
-15% -$1.12M 0.01% 1054
2023
Q2
$8.44M Buy
+679,203
New +$9.17M 0.02% 853
2023
Q1
Sell
-1,776,511
Closed -$25.4M 2971
2022
Q4
$25.4M Buy
1,776,511
+724,950
+69% +$11.4M 0.07% 384
2022
Q3
$26.8M Buy
1,051,561
+496,874
+90% +$12.5M 0.08% 323
2022
Q2
$15.8M Buy
554,687
+223,792
+68% +$7.09M 0.05% 500
2022
Q1
$11.7M Buy
+330,895
New +$11.1M 0.04% 641
2021
Q2
Sell
-465,542
Closed -$16.6M 2202
2021
Q1
$16.6M Sell
465,542
-533,129
-53% -$17.7M 0.08% 325
2020
Q4
$28M Buy
+998,671
New +$27.8M 0.16% 182

Other funds holding MRVI

Balyasny Asset Management's MRVI Position: Q4 2025 in Review

Balyasny Asset Management sold out of Maravai LifeSciences (MRVI) in Q4 2025, closing a stake of 35,821 shares — an estimated $103K sold.

Balyasny Asset Management first reported a position in MRVI in Q4 2020 and held it in 13 quarters. The position peaked at $28M in Q4 2020. 159 funds tracked by Wall St. Rank hold MRVI as of Q4 2025.

  • Balyasny Asset Management reported no remaining Maravai LifeSciences position as of Q4 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 35,821 Maravai LifeSciences shares in Q4 2025, an estimated $103K.
  • Balyasny Asset Management first reported a position in Maravai LifeSciences in Q4 2020 and held it in 13 quarters.
  • Balyasny Asset Management's Maravai LifeSciences position peaked at $28M in Q4 2020.
  • 159 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.